AbbVie Inc. (NYSE: ABBV) announced the official launch in China of Epkinly (epcoritamab), a CD3×CD20 bispecific antibody, for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL). The launch follows approval by China’s National Medical Products Administration (NMPA) on 15 May 2026, making epcoritamab the first bispecific antibody approved in China for second‑line and beyond R/R FL.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | NMPA (China) |
| Product | Epkinly (epcoritamab) – CD3×CD20 bispecific antibody |
| Indication | Adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) |
| Approval Date | 15 May 2026 |
| Launch Date | 26 October 2026 |
| Pivotal Evidence | Phase III EPCORE FL‑1 study |
| Distinction | First bispecific antibody approved in China for second‑line and above R/R FL |
Drug Profile & Mechanism of Action
- Molecule: Epcoritamab, a full‑length, subcutaneously designed CD3×CD20 bispecific antibody originally developed by Genmab.
- Dual Targeting: Simultaneously binds CD3 on T cells and CD20 on B cells, physically bridging the two cell types and inducing T cell–mediated killing of lymphoma B cells.
- Safety Engineering: The Fc region effector function has been silenced, reducing the risk of adverse reactions caused by excessive immune system activation – a design choice aimed at improving the tolerability profile.
- Corporate Lineage: In June 2020, AbbVie and Genmab entered a collaboration worth a total of USD 3.9 billion to jointly develop three next‑generation bispecific products, including epcoritamab.
Clinical Evidence – Phase III EPCORE FL‑1 Study
| Item | Detail |
|---|---|
| Study | EPCORE FL‑1 (Phase III) |
| Population | Relapsed or refractory follicular lymphoma |
| Primary Endpoint | Not disclosed in the announcement |
| Key Efficacy Results | Data not disclosed in the announcement |
| Safety | Fc‑silenced design intended to minimize immune overactivation–related adverse events |
The NMPA approval was granted based on the Phase III EPCORE FL‑1 study, which served as the pivotal trial supporting epcoritamab’s positioning as a second‑line and later therapy for R/R FL in China.
Market Impact & Outlook
- China Lymphoma Landscape: Follicular lymphoma is one of the most common indolent B‑cell non‑Hodgkin lymphomas, and patients who relapse after standard therapy have historically had limited options – epcoritamab introduces T cell–redirecting bispecific therapy as a new treatment class for this population in China.
- First‑Mover Advantage: As the first bispecific antibody approved in China for second‑line and above R/R FL, Epkinly establishes AbbVie’s early position ahead of competing engagers and CAR‑T approaches in the Chinese market.
- Off‑the‑Shelf Convenience: Unlike CAR‑T cell therapy, bispecific antibodies require no patient‑specific manufacturing, enabling broader and faster access across treatment centers.
- Hematology Franchise Expansion: The China launch extends the global commercial footprint of the AbbVie–Genmab bispecific portfolio and reinforces AbbVie’s diversified hematology pipeline built through the USD 3.9 billion partnership.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the commercialization of Epkinly (epcoritamab) in China, market adoption, reimbursement dynamics, and the broader AbbVie–Genmab bispecific collaboration. Actual results may differ materially due to risks including competitive therapies, pricing and access negotiations, clinical and regulatory developments, and evolving treatment guidelines.-Fineline Info & Tech
